Clinical trials: PAH
Pulmonary Arterial Hypertension
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
- Trial name
- RESTORE (NCT04435782)
- Testing
- JNJ-67896049
- Where
- 35 sites in United States, Argentina and 13 more
- Volunteers
- 9 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
TReatment Of Pulmonary HYpertension 1 Study
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and…
- Trial name
- TROPHY (NCT02516722)
- Testing
- Therapeutic Intra-Vascular UltraSound (TIVUS™) System
- Where
- 4 sites in Belgium, Israel and 1 more
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Pulmonary Arterial Hypertension
Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.
- Trial name
- NCT02746237
- Testing
- KAR5585 Capsules
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Karos Pharmaceuticals
Pulmonary Arterial Hypertension
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07441200
- Testing
- NS-863 Low Dose, NS-863 High Dose
- Where
- Japan
- Volunteers
- 135 people
- Sponsor
- NS Pharma, Inc.
Hypertension, Pulmonary
Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00540436
- Testing
- GSK1325760A
- Where
- 15 sites in Japan
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.
- Trial name
- NCT00990314
- Testing
- Beraprost Sodium Modified Release
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 31 people
- Sponsor
- Lung Biotechnology PBC
Primary Pulmonary Hypertension
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT03992755
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 25 sites in United States
- Volunteers
- 92 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
An Open Label Access Study For Subjects Who Completed A1481156
The purpose of this study is to provide sildenafil therapy to subjects who have completed the A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are judged by the Investigator to derive…
- Trial name
- NCT01582438
- Testing
- Access program - sildenafil citrate, Viagra, Revatio
- Where
- India
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Pulmonary Hypertension
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
- Trial name
- INSPIRE (NCT03399604)
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 38 sites in United States
- Volunteers
- 121 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary…
- Trial name
- NCT06603285
- Testing
- Treprostinil
- Volunteers
- 20 people
- Sponsor
- Excelsior
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).
- Trial name
- PATENT-1 (NCT00810693)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 122 sites in United States, Argentina and 28 more
- Volunteers
- 445 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).
- Trial name
- NCT02304198
- Testing
- Udenafil
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Dong-A ST Co., Ltd.
Pulmonary Arterial Hypertension
REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year.
- Trial name
- REPAIR (NCT02310672)
- Testing
- Macitentan
- Where
- 41 sites in United States, Australia and 10 more
- Volunteers
- 89 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH).
- Trial name
- NCT00439946
- Testing
- treprostinil, Crono Five ambulatory pump
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
The purpose of this study is: To assess the effect of BIA 5 1058 400 mg on the pharmacokinetics (PK) of sildenafil. To assess the effect of sildenafil on the PK of BIA 5-1058.
- Trial name
- NCT04994860
- Testing
- BIA 5-1058, Sildenafil
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.